Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-induced B-Cell Acute Lymphoblastic Leukemia
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-0516
Full Text
Open PDFAbstract
Available in full text
Date
August 22, 2019
Authors
Publisher
American Association for Cancer Research (AACR)